secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001759425-24-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum reports 2023 net product sales of $178.9M (+142% YoY); guides 2024 sales $310-320M
--------------------------------------------------------------------------------

- Full-year 2023 total revenue $186.4M, up 142% over 2022; LIVMARLI net sales $141.8M (+89% YoY).
- 2024 global net product sales guidance of $310M to $320M, reflecting continued growth across approved medicines.
- LIVMARLI PFIC PDUFA date on track for March 13, 2024; CHENODAL NDA for CTX planned H1 2024.
- Volixibat VISTAS (PSC) and VANTAGE (PBC) interim analyses expected in first half 2024.
- Appointed Joanne Quan, M.D. as Chief Medical Officer; cash and equivalents $286.3M as of Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942524000005/0001759425-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942524000005/mirm-20240228.htm
  HTML page:      https://secwatch.observer/filing/0001759425-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer